Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mendenhall, W. M.
Right arrow Articles by Hinerman, R. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mendenhall, W. M.
Right arrow Articles by Hinerman, R. W.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 19, Issue 20 (October), 2001: 4029-4036
© 2001 American Society for Clinical Oncology

T1-T2N0 Squamous Cell Carcinoma of the Glottic Larynx Treated With Radiation Therapy

By William M. Mendenhall, Robert J. Amdur, Christopher G. Morris, Russell W. Hinerman

From the Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL.

Address correspondence to William M. Mendenhall, MD, Department of Radiation Oncology, PO Box 100385, Gainesville, FL 32610-0385; email: mendewil{at}shands.ufl.edu

PURPOSE: The end results after radiation therapy for T1-T2N0 glottic carcinoma vary considerably. We analyze patient-related and treatment-related parameters that may influence the likelihood of cure.

PATIENTS AND METHODS: Five hundred nineteen patients were treated with radiation therapy and had follow-up for >= 2 years. Three patients who were disease-free were lost to follow-up at 7 months, 21 months, and 10.5 years. No other patients were lost to follow-up.

RESULTS: Local control rates at 5 years after radiation therapy were as follows: T1A, 94%; T1B, 93%; T2A, 80%; and T2B, 72%. Multivariate analysis of local control revealed that the following parameters significantly influenced this end point: overall treatment time (P < .0001), T stage (P = .0003), and histologic differentiation (P = .013). Patients with poorly differentiated cancers fared less well than those with better differentiated lesions. Rates of local control with laryngeal preservation at 5 years were as follows: T1A and T1B, 95%; T2A, 82%; and T2B, 76%. Cause-specific survival rates at 5 years were as follows: T1A and T1B, 98%; T2A, 95%; and T2B, 90%. One patient with a T1N0 cancer and three patients with T2N0 lesions experienced severe late radiation complications.

CONCLUSION: Radiation therapy cures a high percentage of patients with T1-T2N0 glottic carcinomas and has a low rate of severe complications. The major treatment-related parameter that influences the likelihood of cure is overall treatment time.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Arch Otolaryngol Head Neck SurgHome page
E. D. McCoul and G. Har-El
Meta-analysis of Impaired Vocal Cord Mobility as a Prognostic Factor in T2 Glottic Carcinoma
Arch Otolaryngol Head Neck Surg, May 1, 2009; 135(5): 479 - 486.
[Abstract] [Full Text] [PDF]


Home page
Anticancer ResHome page
G. NISHIMURA, M. TSUKUDA, Y. MIKAMI, H. MATSUDA, C. HORIUCHI, T. TAGUCHI, M. TAKAHASHI, M. KAWAKAMI, M. WATANABE, T. NIHO, et al.
Efficacy of Concurrent Chemoradiotherapy for T1 and T2 Laryngeal Squamous Cell Carcinoma Regarding Organ Preservation
Anticancer Res, February 1, 2009; 29(2): 661 - 666.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. K. Sackett, I. Bairati, F. Meyer, E. Jobin, S. Lussier, A. Fortin, M. Gelinas, A. Nabid, F. Brochet, and B. Tetu
Prognostic Significance of Cyclooxygenase-2 Overexpression in Glottic Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 67 - 73.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. G. Pfister, S. A. Laurie, G. S. Weinstein, W. M. Mendenhall, D. J. Adelstein, K. K. Ang, G. L. Clayman, S. G. Fisher, A. A. Forastiere, L. B. Harrison, et al.
American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
J. Clin. Oncol., August 1, 2006; 24(22): 3693 - 3704.
[Abstract] [Full Text] [PDF]


Home page
Arch Otolaryngol Head Neck SurgHome page
S. A. Pradhan, P. S. Pai, S. I. Neeli, and A. K. D'Cruz
Transoral Laser Surgery for Early Glottic Cancers
Arch Otolaryngol Head Neck Surg, June 1, 2003; 129(6): 623 - 625.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2001 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online